Retinal vein occlusion, homocysteine, and methylene tetrahydrofolate reductase genotype.

PURPOSE The aim of this case-control study was to investigate the relationship between homocysteine (tHcy), 5,10 methylene tetrahydrofolate reductase (MTHFR) C677T genotype, folate and vitamin B12 status, and retinal vein occlusion (RVO). METHODS Subjects with RVO (n = 106) were recruited from outpatient and inpatient sources. Controls (n = 98) were selected to achieve a similar age and sex distribution. Full ocular examination was performed and medical history was taken for each study participant. Plasma and serum samples were analyzed for tHcy level and folate and vitamin B12 status, and extracted DNA was assessed for the MTHFR C677T genotype. RESULTS There was no significant difference in plasma tHcy level or thermolabile MTHFR allele frequency between subjects and controls. Similarly, there was no significant difference in folate or vitamin B12 status between subjects and controls. MTHFR genotype did not affect folate or vitamin B12 concentrations in subjects or controls. However, tHcy was significantly higher in thermolabile homozygotes than in nonthermolabile homozygotes (ratio of geometric means, 1.35; 95% confidence interval [CI], 1.04-1.74; P = 0.024). CONCLUSIONS Hyperhomocysteinemia, the MTHFR C677T mutation, and folate and vitamin B12 status are not important risk factors for RVO in this population.

[1]  B. Giusti,et al.  Genetic determinants of fasting and post-methionine hyperhomocysteinemia in patients with retinal vein occlusion. , 2003, Thrombosis research.

[2]  H. Deutschmann,et al.  Hyperhomocyst(e)inemia, but not methylenetetrahydrofolate reductase C677T mutation, as a risk factor in branch retinal vein occlusion. , 2002, Ophthalmology.

[3]  H. Deutschmann,et al.  Hyperhomocyst(e)inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion , 2002, Graefe's Archive for Clinical and Experimental Ophthalmology.

[4]  R. Howard,et al.  Homocysteine: a risk factor for retinal venous occlusive disease. , 2002, Ophthalmology.

[5]  D. Perry,et al.  Plasma homocysteine, methylene tetrahydrofolate reductase C677T and factor II G20210A polymorphisms, factor VIII, and VWF in central retinal vein occlusion , 2001, The British journal of ophthalmology.

[6]  B. Giusti,et al.  Thrombophilic Risk Factors in Patients with Central Retinal Vein Occlusion , 2001, Thrombosis and Haemostasis.

[7]  M. Cahill,et al.  Thermolabile MTHFR genotype and retinal vascular occlusive disease , 2001, The British journal of ophthalmology.

[8]  M. Tsaloumas,et al.  Nine year follow-up study of morbidity and mortality in retinal vein occlusion , 2000, Eye.

[9]  J. Woodside,et al.  Folate and homocysteine , 2000, Current opinion in clinical nutrition and metabolic care.

[10]  P. Pianka,et al.  Hyperhomocystinemia in patients with nonarteritic anterior ischemic optic neuropathy, central retinal artery occlusion, and central retinal vein occlusion. , 2000, Ophthalmology.

[11]  S. Rauz,et al.  Plasma total homocysteine and retinal vascular disease , 2000, Eye.

[12]  Y. Yazaki,et al.  Homocysteine as a Risk Factor for Restenosis after Coronary Angioplasty , 2000, Thrombosis and Haemostasis.

[13]  J. Herlitz,et al.  Serum homocysteine concentration as an indicator of survival in patients with acute coronary syndromes. , 2000, Archives of internal medicine.

[14]  J. Larsson,et al.  Hyperhomocysteinemia and the MTHFR C677T mutation in central retinal vein occlusion. , 2000, Acta ophthalmologica Scandinavica.

[15]  A. K. Vine.  Hyperhomocysteinemia: a risk factor for central retinal vein occlusion. , 2000, American journal of ophthalmology.

[16]  M. Cahill,et al.  Raised plasma homocysteine as a risk factor for retinal vascular occlusive disease , 2000, The British journal of ophthalmology.

[17]  A. Loewenstein,et al.  Retinal vein occlusion associated with methylenetetrahydrofolate reductase mutation. , 1999, Ophthalmology.

[18]  J. Moisseiev,et al.  Analysis of genetic polymorphisms related to thrombosis and other risk factors in patients with retinal vein occlusion. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[19]  S. Vollset,et al.  Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland Homocysteine Study. , 1998, The American journal of clinical nutrition.

[20]  S. Vollset,et al.  Plasma homocysteine levels and mortality in patients with coronary artery disease. , 1997, The New England journal of medicine.

[21]  J. Witteman,et al.  Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. , 1997, JAMA.

[22]  J. Yarnell,et al.  The common 'thermolabile' variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. , 1996, QJM : monthly journal of the Association of Physicians.

[23]  G. Omenn,et al.  A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. , 1995, JAMA.

[24]  J. Ubbink,et al.  Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. , 1991, Journal of chromatography.

[25]  S S Hayreh,et al.  Systemic diseases associated with various types of retinal vein occlusion. , 2001, American journal of ophthalmology.

[26]  C. Glueck,et al.  Heritable thrombophilia and hypofibrinolysis. Possible causes of retinal vein occlusion. , 1999, Archives of ophthalmology.

[27]  R. Matthews,et al.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase , 1995, Nature Genetics.